The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to assess the effect of Empagliflozin on cardiac mass, volumes,
cardiac biomarkers, metabolism, daily activity level, health-related quality of life in
patients in elderly and obese patients with increased risk of developing heart failure. The
primary hypotheses are that 180 days of treatment with Empagliflozin 10 mg a day will: 1)
reduce left ventricular mass index, and 2) increase peak VO2 (maximal oxygen consumption)
compared with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Jacob Moller
Collaborators:
Danish Heart Foundation Herlev and Gentofte Hospital Hillerod Hospital, Denmark Rigshospitalet, Denmark University Hospital Bispebjerg and Frederiksberg